In another previous study, we identified the same upstream effectors (ERBB2, RABL6, FOXM1 and MITF) to be the most effected by palbociclib treatment in the MDA-MB-231 breast cancer cells, reducing colony formation, cell migration and viability [57]. Here, ERBB2 is linked to breast carcinoma.